| Name | Title | Contact Details |
|---|
The new standard of real estate. We use predictive analytics to anticipate the market and deliver the best matches to you. Make more informed real estate decisions by accessing our robust inventory of properties before they hit the market. Were with y...
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
Full service deed preparation, mobile notary and county recording services currently serving Arizona, Texas, Colorado and Nevada
Traffk is focused on re-engineering the basic building blocks of insurance, beginning with underwriting. Traffk provides alternative insurance data that boost predictive accuracy in modeling and actuarial development, underwriting, and internal inter-d...